Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by New York State Common Retirement Fund

New York State Common Retirement Fund lowered its stake in Integra LifeSciences Holdings Co. (NASDAQ:IARTFree Report) by 3.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 90,533 shares of the life sciences company’s stock after selling 3,458 shares during the period. New York State Common Retirement Fund’s holdings in Integra LifeSciences were worth $3,457,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Jennison Associates LLC grew its position in Integra LifeSciences by 1.9% during the 2nd quarter. Jennison Associates LLC now owns 366,844 shares of the life sciences company’s stock worth $15,088,000 after purchasing an additional 6,758 shares in the last quarter. Bank of Nova Scotia purchased a new position in Integra LifeSciences during the 2nd quarter worth approximately $3,738,000. Bridgefront Capital LLC grew its position in Integra LifeSciences by 299.3% during the 2nd quarter. Bridgefront Capital LLC now owns 16,348 shares of the life sciences company’s stock worth $672,000 after purchasing an additional 12,254 shares in the last quarter. Strs Ohio grew its position in Integra LifeSciences by 39.1% during the 2nd quarter. Strs Ohio now owns 39,051 shares of the life sciences company’s stock worth $1,606,000 after purchasing an additional 10,972 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new position in Integra LifeSciences during the 3rd quarter worth approximately $25,443,000. Institutional investors own 84.13% of the company’s stock.

Analyst Upgrades and Downgrades

IART has been the topic of several research analyst reports. Wells Fargo & Company upgraded shares of Integra LifeSciences from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $40.00 to $49.00 in a report on Tuesday, December 5th. CL King initiated coverage on shares of Integra LifeSciences in a report on Tuesday, November 14th. They set a “buy” rating and a $50.00 price target on the stock. StockNews.com upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, November 13th. Morgan Stanley lowered their price target on shares of Integra LifeSciences from $44.00 to $37.00 and set an “underweight” rating on the stock in a report on Thursday, October 26th. Finally, Truist Financial lifted their price objective on shares of Integra LifeSciences from $44.00 to $46.00 and gave the company a “hold” rating in a research note on Friday, December 22nd. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $46.22.

Get Our Latest Analysis on IART

Integra LifeSciences Stock Up 3.5 %

Shares of IART opened at $43.93 on Tuesday. The company has a 50-day simple moving average of $42.37 and a 200-day simple moving average of $40.73. The firm has a market capitalization of $3.43 billion, a P/E ratio of 36.31, a P/E/G ratio of 1.19 and a beta of 1.18. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.86 and a current ratio of 2.89. Integra LifeSciences Holdings Co. has a 52 week low of $33.44 and a 52 week high of $59.33.

Integra LifeSciences Company Profile

(Free Report)

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

Recommended Stories

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IARTFree Report).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.